Could the PARIS Risk Scores Be Useful for the Choice of Triple versus Dual Antithrombotic Therapy in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention?

抗血栓 医学 传统PCI 经皮冠状动脉介入治疗 心房颤动 内科学 心脏病学 观察研究 心肌梗塞
作者
Leonardo De Luca,Leonardo Bolognese,Andrea Rubboli,Donata Lucci,Domenico Gabrielli,Furio Colivicchi,Michele Massimo Gulizia
出处
期刊:Cardiology [Karger Publishers]
卷期号:147 (2): 133-136 被引量:3
标识
DOI:10.1159/000521673
摘要

Introduction: Current guidelines recommend dual antithrombotic therapy (DAT) for the majority of patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI) and suggest a short course of triple antithrombotic therapy (TAT) for those at very high thrombotic risk (TR) but low bleeding risk (BR). Methods: We analyze if the PARIS ischemic-hemorrhagic scale could be useful for the choice of antithrombotic strategy in patients with acute coronary syndromes and AF treated with coronary stenting enrolled in the prospective, observational, nationwide MATADOR-PCI study. Results: Among the 588 patients discharged alive, a TAT was prescribed in 381 (64.8%) and DAT in 52 (8.8%) patients. According to the PARIS scoring system, 142 (24.2%) were classified as low, 244 (41.5%) as intermediate, and 292 (34.3%) as high TR. In parallel, 87 (14.8%) were categorized in the low, 260 (44.2%) in the intermediate, and 241 (41.0%) in the high-risk stratum for major bleedings. Crossing the various strata of the two PARIS risk scores, the largest group of patients consisted of those at high TR and BR (n = 130, 22%), followed by those at intermediate risk according to both scores (n = 122, 21%). At discharge, TAT was mainly used in patients at intermediate to high BR, while DAT in those at intermediate to high TR but low BR, according to the PARIS score. Conclusion: Our data suggest that some variables associated with increased TR or BR are poorly considered in the daily practice, while the use of PARIS scales could help in the implementation of guidelines’ recommendations.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
建志发布了新的文献求助10
刚刚
酷酷李可爱婕完成签到 ,获得积分10
刚刚
英姑应助白白采纳,获得10
1秒前
满座完成签到,获得积分10
2秒前
杨羕完成签到,获得积分10
3秒前
五六七完成签到,获得积分10
3秒前
周少完成签到,获得积分10
3秒前
兴奋的若菱完成签到 ,获得积分10
3秒前
幸福广山完成签到,获得积分10
5秒前
HMethod完成签到 ,获得积分10
7秒前
Y123完成签到,获得积分10
7秒前
8秒前
ersan完成签到,获得积分10
9秒前
Hello应助nkmenghan采纳,获得30
10秒前
10秒前
10秒前
粗心的听安完成签到,获得积分10
10秒前
念姬完成签到 ,获得积分10
11秒前
量子星尘发布了新的文献求助10
11秒前
12秒前
13秒前
指哪打哪完成签到,获得积分10
13秒前
13秒前
静静子发布了新的文献求助100
14秒前
Ray完成签到 ,获得积分10
15秒前
文静的天蓝完成签到,获得积分10
15秒前
tszjw168完成签到 ,获得积分10
16秒前
手打鱼丸完成签到 ,获得积分10
17秒前
体贴凌柏发布了新的文献求助10
17秒前
开心快乐发大财完成签到,获得积分10
19秒前
萌萌哒完成签到,获得积分10
19秒前
小龅牙吖完成签到,获得积分10
19秒前
Propitious完成签到,获得积分10
20秒前
徐先生1106完成签到,获得积分10
20秒前
Epiphany完成签到,获得积分10
21秒前
舒心的久完成签到 ,获得积分10
21秒前
闻巷雨完成签到 ,获得积分10
23秒前
北风完成签到,获得积分10
24秒前
xliiii完成签到,获得积分10
24秒前
时光倒流的鱼完成签到,获得积分10
25秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038303
求助须知:如何正确求助?哪些是违规求助? 3576013
关于积分的说明 11374210
捐赠科研通 3305780
什么是DOI,文献DOI怎么找? 1819322
邀请新用户注册赠送积分活动 892672
科研通“疑难数据库(出版商)”最低求助积分说明 815029